Ultragenyx Pharmaceutical Inc. Contracts & Agreements

Amended and Restated 2023 Incentive Plan (Filed With SEC on June 21, 2024)

Underwriting Agreement, dated as of June 13, 2024, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and TD... (Filed With SEC on June 17, 2024)

Form of Pre-Funded Warrant (Filed With SEC on June 17, 2024)

Commercial Supply Agreement, dated June 19, 2023, between Ultragenyx Pharmaceutical Inc. and IOI Oleo GmbH (Filed With SEC on February 21, 2024)

Form of Incentive Stock Option Agreement (2023 Plan) (Filed With SEC on February 21, 2024)

Form of Non Statutory Stock Option Agreement (Employees)(2023 Plan) (Filed With SEC on February 21, 2024)

Form of Restricted Stock Unit Agreement (Employees)(2023 Plan) (Filed With SEC on February 21, 2024)

Form of Non-Statutory Stock Option Agreement (Annual Grant for Directors) (2023 Plan) (Filed With SEC on February 21, 2024)

Form of Restricted Stock Unit Agreement (Annual Grant for Directors) (2023 Plan) (Filed With SEC on February 21, 2024)

Form of Non-Statutory Stock Option Agreement (Grant for New Directors)(2023 Plan) (Filed With SEC on February 21, 2024)

Form of Restricted Stock Unit Agreement (Grant for New Directors) (2023 Plan) (Filed With SEC on February 21, 2024)

Underwriting Agreement, dated as of October 18, 2023, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and... (Filed With SEC on October 23, 2023)

Form of Pre-Funded Warrant (Filed With SEC on October 23, 2023)

Amendment dated September 6, 2023 to the Offer Letter between Howard Horn and Ultragenyx Pharmaceutical Inc. dated June 22, 2023 (Filed With SEC on September 8, 2023)

Amendment No. 13 to Collaboration and License Agreement, effective as of May 16, 2023, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin, Co., Ltd (Filed With SEC on August 4, 2023)

Offer Letter between Howard Horn and Ultragenyx Pharmaceutical Inc. dated June 22, 2023 (Filed With SEC on July 12, 2023)

Amendment No. 12 to Collaboration and License Agreement, effective as of September 29, 2022, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on November 3, 2022)

Amendment No. 2, dated September 13, 2022, to Executive Employment Agreement by and between Ultragenyx Pharmaceutical Inc. and Emil D. Kakkis, M.D., Ph.D (Filed With SEC on November 3, 2022)

Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Camille Bedrosian, M.D (Filed With SEC on November 3, 2022)

Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Mardi C. Dier (Filed With SEC on November 3, 2022)

Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Thomas Kassberg (Filed With SEC on November 3, 2022)

Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Karah Parschauer (Filed With SEC on November 3, 2022)

Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Dennis Huang (Filed With SEC on November 3, 2022)

Amendment No. 3, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on November 3, 2022)

Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and John R. Pinion II (Filed With SEC on November 3, 2022)

Royalty Purchase Agreement by and among Rare Delaware Inc., Ultragenyx Pharmaceutical Inc. and OCM LS23 Holdings LP dated as of July 14, 2022 (Filed With SEC on July 29, 2022)

Form of Performance Stock Unit Agreement (2022) (Filed With SEC on May 6, 2022)

Amendment No. 11 to Collaboration and License Agreement, effective as of December 17, 2021 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 15, 2022)

Second Amendment to Option and License Agreement, dated December 17, 2021, by and between REGENXBIO, Inc. and Ultragenyx Pharmaceutical Inc (Filed With SEC on February 15, 2022)

Amendment No. 1 to the Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan (Filed With SEC on November 3, 2021)

Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan (Filed With SEC on August 3, 2021)

Form of Non-Statutory Stock Option Agreement (Annual Grant for Directors) (Filed With SEC on August 3, 2021)

Form of Restricted Stock Unit Agreement (Annual Grant for Directors) (Filed With SEC on August 3, 2021)

Form of Non-Statutory Stock Option Agreement (Grant for New Directors) (Filed With SEC on August 3, 2021)

Form of Restricted Stock Unit Agreement (Grant for New Directors) (Filed With SEC on August 3, 2021)

Open Market Sale Agreement, dated May 7, 2021, by and between Ultragenyx Pharmaceutical Inc. and Jefferies LLC (Filed With SEC on May 7, 2021)

Form of Performance Stock Unit Agreement (2021) (Filed With SEC on May 5, 2021)

License Agreement, dated as of September 20, 2012, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)

Amendment to the License Agreement, dated as of March 22, 2013, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)

Master Services Agreement, dated April 8, 2019, between Ultragenyx Pharmaceutical Inc. and Aenova Haupt Pharma Wolfratshausen GmbH (Filed With SEC on February 12, 2021)

Employment Inducement Plan (Filed With SEC on February 12, 2021)

Form of Non Statutory Stock Option Agreement (Inducement Plan) (Filed With SEC on February 12, 2021)

Form of Non Statutory Stock Option Agreement (Inducement Plan) (ex-US) (Filed With SEC on February 12, 2021)

Form of Restricted Stock Unit Agreement (Inducement Plan) (Filed With SEC on February 12, 2021)

Form of Restricted Stock Unit Agreement (Inducement Plan)(ex-US) (Filed With SEC on February 12, 2021)

Lease Agreement, dated December 15, 2019, between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)

First Amendment, dated September 20, 2020, to the Lease Agreement dated December 15, 2019 between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)

Second Amendment, dated October 21, 2020, to the Lease Agreement dated December 15, 2019 between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)

Underwriting Agreement, dated as of October 28, 2020, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and... (Filed With SEC on November 2, 2020)

Fourth Amended and Restated Amendment to Lease Agreement between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No. 20, LLC (Filed With SEC on October 27, 2020)

Amendment dated October 9, 2020 to the Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on October 13, 2020)

Amendment No. 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020, as amended on August... (Filed With SEC on October 13, 2020)

Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on September 2, 2020)

Amendment dated as of August 28, 2020 to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020 (Filed With SEC on September 2, 2020)

Equity Purchase Agreement, dated as of June 18, 2019 by and among Ultragenyx Pharmaceutical Inc. and Arcturus Therapeutics Ltd (Filed With SEC on July 31, 2020)

Third Amendment, dated as of July 29, 2019, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No., LLC (Filed With SEC on July 31, 2020)

Fourth Amendment, dated as of March 31, 2020, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No., LLC (Filed With SEC on July 31, 2020)

Amendment 10 to Collaboration and License Agreement effective as of April 1, 2020 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on May 7, 2020)

Form of Performance Stock Unit Agreement (2020) (Filed With SEC on May 7, 2020)

Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc., dated March 5, 2020 (Filed With SEC on March 6, 2020)

Description of Common Stock (Filed With SEC on February 14, 2020)

Amendment No. 9 to Collaboration and License Agreement, effective December 23, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 14, 2020)

Royalty Purchase Agreement, dated as of December 17, 2019, between Ultragenyx Pharmaceutical Inc. and RPI Finance Trust (Filed With SEC on February 14, 2020)

Office Lease, dated April 19, 2019, between Ultragenyx Pharmaceutical Inc. and Woburn MCB II, LLC (Filed With SEC on February 14, 2020)

Commercial Lease, dated July 2, 2018, between Ultragenyx Pharmaceutical Inc. and 32 Leveroni LLC (Filed With SEC on February 14, 2020)

Separation Agreement and General Release between Wladimir Hogenhuis, M.D. and Ultragenyx Pharmaceutical Inc., dated November 22, 2019 (Filed With SEC on November 25, 2019)

Amendment No. 8 to Collaboration and License Agreement, effective as of July 4, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin... (Filed With SEC on August 2, 2019)

Addendum #6 to Standard Lease, effective as of April 29, 2019, by and between Ultragenyx Pharmaceutical Inc. and Condiotti Enterprises, Inc (Filed With SEC on August 2, 2019)

Offer Letter, dated May 16, 2017, by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)

Addendum #1, dated August 8, 2017, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)

Addendum #2, dated June 19, 2019, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)

Amended and Restated Collaboration and License Agreement, dated June 3, 2019, between Ultragenyx Pharmaceutical Inc. and Bayer Healthcare LLC (Filed With SEC on August 2, 2019)

First Amendment to Option and License Agreement entered into March 18, 2019 between REGENXBIO Inc. and Ultragenyx Pharmaceutical Inc. (as assignee of Dimension Therapeutics, Inc.) (Filed With SEC on May 7, 2019)

Amendment No. 6 to Collaboration and License Agreement, effective as of February 1, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)

Amendment No. 7 to Collaboration and License Agreement, entered into as of December 5, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)

Form of Performance Stock Unit Agreement (2019) (Filed With SEC on May 7, 2019)

Underwriting Agreement, dated as of February 26, 2019, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner... (Filed With SEC on March 1, 2019)

Third Lease Amendment to the Lease between Ultragenyx Pharmaceutical Inc. and Rivertech Associates II, LLC, effective December 31, 2018 (Filed With SEC on February 20, 2019)

Offer Letter, dated August 2, 2018 (Filed With SEC on September 17, 2018)

Amendment No. 5 to Collaboration and License Agreement, effective as of April 30, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on August 3, 2018)

Addendum 4 to Standard Lease, effective April 1, 2018, between Ultragenyx Pharmaceutical Inc. and Condiotti Enterprises, Inc (Filed With SEC on August 3, 2018)

Second Amendment to Lease Agreement, made July 1, 2018, between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No. 20, LLC (Filed With SEC on August 3, 2018)

First Amendment to Lease Agreement, dated March 20, 2018, between ARE-MA Region No. 20, LLC and Ultragenyx Pharmaceutical Inc (Filed With SEC on May 8, 2018)

Amendment No. 1 to Sales Agreement, dated as of March 30, 2018, between Ultragenyx Pharmaceutical Inc. and Cowen and Company, LLC (Filed With SEC on March 30, 2018)

Asset Purchase Agreement, dated December 14, 2017, among Ultragenyx Pharmaceutical Inc., Ultragenyx International UX003 Ltd. and Novartis Pharma AG (Filed With SEC on February 21, 2018)

Amendment No. 2 to Collaboration and License Agreement, effective as of November 28, 2016, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)

Amendment No. 3 to Collaboration and License Agreement, effective September 29, 2017, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)

Amendment No. 4 to Collaboration and License Agreement, effective as of January 29, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on February 21, 2018)

Supply Agreement, dated as of November 19, 2012, between Ultragenyx Pharmaceutical Inc. and CREMER OLEO GmbH & Co KG (Filed With SEC on February 21, 2018)

Underwriting Agreement, dated as of January 23, 2018, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated,... (Filed With SEC on January 26, 2018)

Agreement and Plan of Merger, dated October 2, 2017, among the Company, Purchaser and Dimension (Filed With SEC on October 3, 2017)

ULTRAGENYX PHARMACEUTICAL INC. $150,000,000 SALES AGREEMENT (Filed With SEC on July 28, 2017)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN (Filed With SEC on February 17, 2017)

ULTRAGENYX PHARAMACEUTICAL INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (amended as of June 9, 2016) (Filed With SEC on February 17, 2017)

Turning good science into great medicine (Filed With SEC on February 17, 2017)

AMENDMENT NO. 4 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on February 17, 2017)

ULTRAGENYX PHARMACEUTICAL INC. $150,000,000 SALESAGREEMENT (Filed With SEC on July 5, 2016)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) (Filed With SEC on May 10, 2016)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) (ex-U.S.) (Filed With SEC on May 10, 2016)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (EMPLOYEES) (ex-U.S.) (Filed With SEC on May 10, 2016)

Addendum One (Filed With SEC on February 26, 2016)

ADDENDUM TWO (Filed With SEC on February 26, 2016)

Addendum #5 To The Lease Dated on or about July 1, 2011 By and Between Condiotti Enterprises, Inc. (Lessor) And Ultragenyx Pharmaceutical Inc. (Lessee) (Filed With SEC on February 26, 2016)

LEASE AGREEMENT BETWEEN MARINA BOULEVARD PROPERTY, LLC, AS LANDLORD, AND ULTRAGENYX PHARMACEUTICAL INC., AS TENANT DATED December 8, 2015 TABLE OF CONTENTS (Filed With SEC on February 26, 2016)

CONFIDENTIAL TREATMENT REQUESTED [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential... (Filed With SEC on November 10, 2015)

AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 10, 2015)

AMENDMENT NO. 3 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 10, 2015)

Ultragenyx Pharmaceutical Inc. (Filed With SEC on August 14, 2015)

ULTRAGENYX PHARMACEUTICAL INC. 2,200,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on July 21, 2015)

Amendment 1 (this Amendment) to the Development and Clinical Supply Agreement with the Contract Number: E86A1D4C-B3F9 Between Ultragenyx Pharmaceutical Inc. 60 Leveroni Court,... (Filed With SEC on March 27, 2015)

Addendum #4 To The Lease Dated on or about July 1, 2011 By and Between Condiotti Enterprises, Inc. (Lessor) And Ultragenyx Pharmaceutical Inc. (Lessee) (Filed With SEC on March 13, 2015)

ULTRAGENYX PHARMACEUTICAL INC. 3,000,000 Shares of Common Stock Underwriting Agreement (Filed With SEC on February 10, 2015)

AMENDMENT NO. 2 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 10, 2014)

FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on August 11, 2014)

AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 11, 2014)

ULTRAGENYX PHARMACEUTICAL INC. [] Shares of Common Stock Underwriting Agreement (Filed With SEC on July 7, 2014)

Addendum #3 To The Lease By and Between Condiotti Enterprises, Inc. (Lessor) And Ultragenyx Pharmaceutical,Inc. (Lessee) Dated on or about July 1, 2011 (Filed With SEC on February 25, 2014)

ULTRAGENYX PHARMACEUTICAL INC. [ ] Shares of Common Stock Underwriting Agreement (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (EMPLOYEES) (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (DIRECTORS) (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (DIRECTORS) (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARAMACEUTICAL INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on January 17, 2014)

FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on January 17, 2014)

ULTRAGENYX PHARMACEUTICAL INC. CORPORATE BONUS PLAN (Filed With SEC on January 17, 2014)

COLLABORATION AND LICENSE AGREEMENT by and between KYOWAHAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013 (Filed With SEC on December 23, 2013)

LICENSE AGREEMENT (Filed With SEC on December 23, 2013)

LicenseAgreement (Filed With SEC on December 23, 2013)

COLLABORATION AND LICENSE AGREEMENT BETWEEN NOBELPHARMA CO.,LTD. AND ULTRAGENYX PHARMACEUTICALS, INC (Filed With SEC on December 23, 2013)

LICENSE AGREEMENT (Filed With SEC on December 23, 2013)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on December 23, 2013)

SUPPLY AGREEMENT between CREMER OLEOGmbH & Co KG, Glockengiesserwall 3, 20095 Hamburg, Germany hereinafter referred to as Cremer and UltragenyxPharmaceutical Inc, 60 Leveroni... (Filed With SEC on December 23, 2013)

State of Delaware (Filed With SEC on November 8, 2013)

WARRANT TO PURCHASE SERIES A PREFERRED STOCK OF ULTRAGENYX PHARMACEUTICAL INC. (Filed With SEC on November 8, 2013)

ULTRAGENYX PHARMACEUTICAL INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT Dated as of December 18, 2012 TABLE OF CONTENTS (Filed With SEC on November 8, 2013)

COLLABORATION AND LICENSE AGREEMENT by and between KYOWAHAKKO KIRIN CO., LTD. and ULTRAGENYX PHARMACEUTICAL INC. Dated August 29, 2013 (Filed With SEC on November 8, 2013)

LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

LicenseAgreement (Filed With SEC on November 8, 2013)

AMENDMENT LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

COLLABORATION AND LICENSE AGREEMENT BETWEEN NOBELPHARMA CO.,LTD. AND ULTRAGENYX PHARMACEUTICALS, INC (Filed With SEC on November 8, 2013)

LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 8, 2013)

SUPPLY AGREEMENT between CREMER OLEOGmbH & Co KG, Glockengiesserwall 3, 20095 Hamburg, Germany hereinafter referred to as Cremer and UltragenyxPharmaceutical Inc, 60 Leveroni... (Filed With SEC on November 8, 2013)

Development and Clinical Supply Agreement Contract Number: E86A1D4C-B3F9 Between RentschlerBiotechnologie GmbH - and - Ultragenyx Pharmaceutical Inc. (Filed With SEC on November 8, 2013)

ULTRAGENYX PHARMACEUTICAL, INC. 2011 EQUITY INCENTIVE PLAN ARTICLE 1 PURPOSE (Filed With SEC on November 8, 2013)

ULTRAGENYX PHARMACEUTICAL INC. AMENDMENT TO THE 2011 EQUITYINCENTIVE PLAN (Filed With SEC on November 8, 2013)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on November 8, 2013)

LAKEPOINT BUSINESS PARK STANDARD LEASE BASICLEASE INFORMATION (Filed With SEC on November 8, 2013)

License and Services Agreement (Filed With SEC on November 8, 2013)

AMENDMENT NO. 1 TO LICENSE AND SERVICES AGREEMENT (Filed With SEC on November 8, 2013)

Category

Industry

Companies

Contracts

Ultragenyx Pharmaceutical Inc. Contracts & Agreements